News

Proof-of-concept Phase II trial AdrenOSS-2 is assessing first-in-class antibody Adrecizumab, designed to restore and maintain vascular integrity AdrenOSS-2 trial design and Adrecizumab mode of action will be presented at the European Society of Intensive Care

Hennigsdorf/Berlin (Germany), August 29, 2019 – Adrenomed AG, the vascular integrity company, announced today that its Supervisory Board has appointed two new members of the Executive Board. Dr. Jens Schneider-Mergener is Chief Executive Officer (CEO)

  Hennigsdorf (Germany), August 13, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation at four upcoming conferences in Europe. Adrenomed representatives will be available for networking and one-to-one meetings at the

  Hennigsdorf (Germany), May 6, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation at three upcoming conferences in Europe and the USA. Adrenomed representatives will be available for one-on-one meetings at

AdrenOSS-II trial continues as planned after positive interim efficacy analysis triggered by the treatment of 50% of randomized patients Proof-of-concept trial design testing Adrecizumab in early septic shock presented at International Symposium on Intensive Care

  Hennigsdorf (Germany), March 12, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation in three upcoming conferences in Europe. Adrenomed representatives will be available for one-on-one meetings at these events. 12th

Ongoing proof-of-concept trial AdrenOSS-II testing Adrecizumab in early septic shock Adrecizumab is a first-in-class antibody targeting Adrenomedullin, to rescue vascular function Vascular integrity, regulated by Adrenomedullin, is key to preventing vascular leakage and septic shock

Adrenomed AG, the vascular integrity company, today announced the closing of a EUR 24 million series D financing round co-led by Wellington Partners and HBM Healthcare Investments as new investors.

Three scientific papers report how the monoclonal therapeutic antibody Adrecizumab reverses vascular hyperpermeability in sepsis. Adrecizumab acts through stabilization of the vasoactive peptide hormone adrenomedullin and its redistribution from tissue into blood plasma without blocking